

GOG Partners Investigator Council

Kathleen Moore, MD Thomas Herzog, MD



The IC

Purpose: To identify high quality investigators at GOG-F sites who have demonstrated a commitment to high accrual to GOG-P clinical trials & enable them to act in an advisory role to sponsors & to GOG-P with the ultimate goal of increasing the FDA approval of new agents for gynecologic cancers.

Vision: To establish GOG-P as the foremost organization for high quality, efficient and cutting-edge gynecologic cancer clinical trial intellect and operations.





Investigator Council

Charles Anderson

Willamette Valley Cancer Institute

Victoria Bae Jump

University of North Carolina at Chapel Hill

Joyce Barlin

Women's Cancer Care Associates

Destin Black

Willis-Knighton Medical Center

Stephanie Blank

Icahn School of Medicine at Mt. Sinai

Michael Bookman

Kaiser Permanente Northern California

William Bradley

Medical College of Wisconsin

Dana Chase

Arizona Oncology/US Oncology Network

Noelle Cloven

Texas Oncology Fort Worth

Linda Duska

University of Virginia

Melissa Geller

University of Minnesota

Sharad Ghamande

Augusta University (GRU)

Rachel Grisham

Memorial Sloan Kettering Cancer Center

Camille (Gunderson) Jackson

University of Oklahoma, Stephenson Cancer Center

John Hays

The Ohio State University James Cancer Center

Amanda Jackson

University of Cincinnati

Gottfried Konecny

University of California Los Angeles

Sharyn Lewin

Holy Name Medical Center

Cara Matthews

Womans & Infants' Hospital of Rhode Island

Jyoti Mayadev

UC San Diego

Colleen McCormick

Legacy Cancer Center

Michael McHale

University of California, San Diego; Moores Cancer Center

Robert Morris

Wayne State University School of Medicine

Tashanna Myers

Baystate Medical Center

R. Wendell Naumann

Levine Cancer Inst, Atrium Health

Richard Penson

MGH/Harvard

Emily Prendergast

Minnesota Oncology

Debra Richardson

Stephenson Cancer Center, University of Oklahoma

Health Sciences Center

Mark Shahin

Abington Jefferson Hospital

Fiona Simpkins

University of Pennsylvania

Krishnansu Tewari

University of California, Irvine

Premal Thaker

Washington University School of Medicine

Jessica Thomes-Pepin

Minnesota Oncology – US Oncology

Robert Wenham

Moffit Cancer Center





IC INVOLVEMENT

- Optimizing Accrual
- Reporting Site Metrics
- Streamlining Study
 Start-Up

AMBASSADOR

PARTICIPATION

- Building Capacity
- Standardizing Best Practices
- Participation in Study Design
 Execution

- Engage Industry& OtherStakeholders
- Regulatory
 Activities

INITIATIVE



GOG Partners Investigator Council

PATIENTS

Recruiting, Patient Education, Eligibility, Accrual, Protocol Reminders to Staff

FINANCE

Funding, Budget, Finance Issues, HMO

Biggest Challenges

SUPPORT

Staff Support, Availability of Trials, Communication & System Issues, Training, Need for Research Nurses, Logistics

OTHER

COVID-19, Complexity of Trials, Multi-Site Institution, Other Work, Competing Trials, Time, Regulatory Requirements



GOG Partners IC Committees

Clinical Trial Equity

Engaging sites across network and recruiting new sites to ensure GOG P has trial available to all geographic, socioeconomic and ethnic populations

Business Development

Engaging new assets and companies; advising on opportunities for GOG-P; Distributing branded slides of active studies etc.

Engagement Opportunities

Site Engagement

Site Engagement & Metrics- Defining key analytics; Setting process to compile info from sites; Disseminating best practices

Trial Challenges

Overcoming Challenges of Conducting Clinical trials- SIP; Pandemic; etc.





THANK YOU

